Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.

T. Golan, Z. S. Kanji, R. Epelbaum, N. Devaud, E. Dagan, S. Holter, D. Aderka, S. Paluch-Shimon, B. Kaufman, R. Gershoni-Baruch, D. Hedley, M. J. Moore, E. Friedman, S. Gallinger

Research output: Contribution to journalArticlepeer-review

Abstract

The BRCA1/2 proteins are involved in regulation of cellular proliferation by DNA damage repair via homologous recombination. Therefore, BRCA1/2 mutation carriers with pancreatic cancer may have distinct biologic outcomes. Patients with BRCA1/2-associated pancreatic ductal adenocarcinoma (PDAC) diagnosed between January 1994 and December 2012 were identified from databases at three participating institutions. Clinical data were collected. Disease-free survival and overall survival (OS) were analysed. Overall, 71 patients with PDAC and BRCA1 (n=21), BRCA2 (n=49) or both (n=1) mutations were identified. Mean age at diagnosis was 60.3 years (range 33-83), 81.7% (n=58) had any family history of malignancy; 30% (n=21) underwent primary resection. Out of 71 participants, 12 received experimental therapy; one patient had missing data, these 13 cases were excluded from OS analysis. Median OS for 58 patients was 14 months (95% CI 10-23 months). Median OS for patients with stage 1/2 disease has not been reached with 52% still alive at 60 months. Median OS for stage 3/4 was 12 months (95% CI 6-15). Superior OS was observed for patients with stage 3/4 treated with platinum vs those treated with non-platinum chemotherapies (22 vs 9 months; P=0.039). Superior OS was observed for advanced-disease BRCA-associated PDAC with platinum exposure.

Original languageEnglish
Pages (from-to)1132-1138
Number of pages7
JournalBritish Journal of Cancer
Volume111
Issue number6
DOIs
StatePublished - 9 Sep 2014

Fingerprint

Dive into the research topics of 'Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.'. Together they form a unique fingerprint.

Cite this